A Tale Of Two Systems

NIH 1. Proposal arrives at NIH and is sent to appropriate study section. 2. Scientific review administrator appoints two study section members to serve as primary and secondary reviewers of the application. 3. Study section convenes. Primary and secondary reviewers present reports on proposal, followed by open discussion. Study section may vote to reject or defer action on application. Otherwise, panelists assign it a priority score. 4. Proposal proceeds to National Advisory Council (NAC) o

Written byJeff Seiken
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

1. Proposal arrives at NIH and is sent to appropriate study section.

2. Scientific review administrator appoints two study section members to serve as primary and secondary reviewers of the application.

3. Study section convenes. Primary and secondary reviewers present reports on proposal, followed by open discussion. Study section may vote to reject or defer action on application. Otherwise, panelists assign it a priority score.

4. Proposal proceeds to National Advisory Council (NAC) of appropriate institute. NAC--composed of about eight independent scientists and four people from the lay community--checks that proposal received a fair hearing from the study section and offers its own assessment based on proposal's relevance to institute's overall goals. NAC may not change priority scores, but it can recommend that proposals be funded out of order.

5. Institute staff makes final decision based on proposal's priority score and advice from study section and NAC.

NSF 1. Proposal ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies